Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Sleep apnea stories

Aug 31, 2026

Sleep apnea pill reduces breathing events by 44% in phase 3 trial

A once-nightly pill cut breathing interruptions by approximately 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity by strengthening airway muscles.

Aug 31, 2026·2 sources
00

Top claims

  • ▪The most frequently reported side effects of AD109 in the phase 3 trial were dry mouth, nausea, insomnia, and difficulty urinating
  • ▪Participants receiving a placebo in the SynAIRgy trial experienced an 18% reduction in their apnea-hypoxia index, compared to the 44% reduction seen in the AD109 group
  • ▪Continuous Positive Airway Pressure remains the gold standard treatment for obstructive sleep apnea, but many patients remain untreated or undertreated due to difficulty tolerating the device

Subtopics

Clinical evaluation1Clinical Trial Design & Evaluation1Clinical trials1Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1Sleep & circadian rhythm1Sleep medications1

Related timelines

Congress

110 stories

Iran War

209 stories

Trump administration

160 stories

US midterm elections

102 stories

AI Data Center Gold Rush

111 stories